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The decision to oﬀ er radiotherapy in patients with connective tissue diseases continues to be challenging. 
Radiotherapy might trigger the onset of connective tissue diseases by increasing the expression of self-antigens, 
diminishing regulatory T-cell activity, and activating eﬀ ectors of innate immunity (dendritic cells) through Toll-like 
receptor-dependent mechanisms, all of which could potentially lead to breaks of immune tolerance. This potential 
risk has raised some debate among radiation oncologists about whether patients with connective tissue diseases can 
tolerate radiation as well as people without connective tissue diseases. Because the number of patients with cancer 
and connective tissue diseases needing radiotherapy will probably increase due to improvements in medical 
treatment and longer life expectancy, the issue of interactions between radiotherapy and connective tissue diseases 
needs to be clearer. In this Review, we discuss available data and evidence for patients with connective tissue diseases 
treated with radiotherapy.
Introduction
Connective tissue diseases are a heterogeneous group 
of autoimmune rheumatic diseases characterised by 
immune system dysregulation and the development of 
autoantibodies. Patients typically alternate between 
active or symptomatic periods and non-active or 
quiescent phases. Connective tissue diseases have 
historically been considered an absolute or relative 
contraindication to radiotherapy because of the 
hypothesis of a greater risk of severe radiotherapy-
related acute and late complications.
Few reports have been made of the outcomes of 
patients with newly diagnosed connective tissue diseases 
(or exacerbation of pre-existing disease) who need 
radiotherapy (table 1, 2).1–21 Although an analysis of the 
little available data shows that risk of radiotherapy 
toxicity in patients with connective tissue diseases seems 
to be based largely on anecdotal evidence, radiation 
oncologists remain hesitant. In 1998, the American 
College of Radiology22 concluded that, “a history of 
collagen vascular disease is a relative contraindication to 
breast conservation treatment because published reports 
indicate that such patients tolerate irradiation poorly. 
Most radiation oncologists will not treat patients with 
scleroderma or active systemic lupus erythematosus, 
considering either an absolute contraindication.” 
Thus, radiotherapy has been under used in patients with 
connective tissue diseases who have cancer.16
With improved medical treatments, prognosis for 
patients with connective tissue diseases has improved. 
The 5-year survival in systemic lupus erythematosus has 
increased from about 40% in the 1950s, to 90% in the 
1980s, to more than 90–95% nowadays.23 Therefore, a 
higher number of patients with connective tissue 
diseases are expected to be diagnosed with cancer and 
will potentially be eligible for oncological treatment, 
including radiotherapy. Substantial improvements have 
been made in radiation technology, including the 
development of intensity-modulated radiotherapy and 
image-guided radiotherapy. These techniques are 
available in clinical practice, potentially minimising 
acute and late local side-eﬀ ects. Thus, new radiotherapy 
techniques could be considered feasible even in patients 
with connective tissue diseases who have cancer. In this 
Review, we analyse evidence and discuss the available 
data for radiotherapy in patients with connective 
tissue diseases.
Connective tissue diseases, cancer environments, 
and radiation interactions
Connective tissue diseases are chronic and debilitating 
autoimmune disorders that cause substantial morbidity 
and mortality and disproportionately aﬀ ect women. 
These diseases include rheumatoid arthritis, systemic 
sclerosis, scleroderma, systemic lupus erythematosus, 
derma tomyositis, and vasculitis. Connective tissue 
diseases often develop after environmental triggering via 
cellular pathways in genetically susceptible individuals 
with disease-associated polymorphisms.24 However, the 
speciﬁ c cellular and molecular mechanisms leading to 
connective tissue diseases, and factors that establish 
involved organs are involved, are poorly understood.
Associations between connective tissue diseases and 
cancer are being increasingly investigated. Links between 
them are multifaceted and have diﬀ erent relationships in 
terms of frequency, timing, and type of cancers. Several 
studies have highlighted the dynamic and bidirectional 
interactions occurring at the cancer–immune system 
interface that might be relevant to the origins of 
autoimmunity.25 Data for patients with systemic sclerosis 
and concomitant cancer suggest that, in some cases, 
autoimmunity might be triggered by an autoantigen 
mutation in the patient’s cancer.26,27 Also, connective tissue 
diseases might cause changes in immune function that 
could be aﬀ ected by immunosuppressive therapy.24 
Although the evidence was not overwhelming, some 
investigators have reported that these changes in immune 
function did aﬀ ect radiotherapy toxicity.28 This bidirectional 
hypothesis was based on the idea that some connective 
tissue diseases share a common pathological pathway of 
vascular obliteration and ﬁ brosis due to heightened 
inﬂ ammation and a clinical pattern of possible systemic 
involvement. The potential for radiotherapy to augment 
these pathological changes became a topic of investigation. 
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Radiotherapy acutely aﬀ ects early responding tissues, such 
as the basal dermis and oral and gastric mucosa, by 
reducing proliferation. Radiation-induced obliteration of 
capillaries and small vessels is also well documented.28 
In patients with connective tissue diseases, these acute 
eﬀ ects might act in conjunction with immune-related 
damage caused by immune complex deposition, 
complement cascade activation, and inﬁ ltrating inﬂ am-
matory cells (ﬁ gure 1). Such common targeting might be 
additive to typical radiation-induced acute tissue injuries.11 
The additive injury induced by both radiation and the 
pre-existing connective tissue diseases might also help to 
explain the potentially increased late eﬀ ects noted in some 
of these patients after radiotherapy.3 Radiotherapy might 
trigger the onset of connective tissue diseases by enhancing 
the expression of self-antigens (eg, from apoptotic 
cell debris), diminishing regulatory T-cell activity, and 
activating eﬀ ectors of innate immunity such as dendritic 
cells through Toll-like receptor-dependent mechanisms, all 
of which could potentially lead to a break of immune 
tolerance.25 This potential mechanism has raised a debate 
among radiation oncologists about whether patients with 
connective tissue diseases tolerate radiation as well as 
people with no connective tissue disease.29
Experimental evidence supports the hypothesis that the 
immune system is able to repress tumour cells and that 
immune surveillance has a key role in the identiﬁ cation 
and elimination of cancer cells.30 Three diﬀ erent phases 
have been described in the interaction between cancer 
cells and the immune system: elimination (which is still 
considered the cornerstone in the immune surveillance 
process), equilibrium between the immune system and 
cancer cells, and escape.30 Immune surveillance is 
considered a complex process involving diﬀ erent immune 
system cells—ie, CD8 cells, natural killer cells, CD4 cells, 
macrophages, and B lymphocytes.30 After radiotherapy, 
the disruption of the tissue architecture is associated with 
changes in blood ﬂ ow (zones with hyperperfusion and 
hypoxia) and lymphatic function and an increase in 
interstitial pressure.31 Additionally, irradiation of the 
tumour and its microenvironment is associated with 
the proliferation of inﬂ ammatory signals detected by the 
immune system.32 The resulting production of cytokines 
and chemokines then attracts antigen-presenting cells 
(dendritic cells) that, after uptake of tumour-associated 
antigens, cause CD8 activation involved in tumour killing 
(ﬁ gure 1).33,34
Evidence is also increasing that inﬂ ammation contributes 
to cancer development and that cancer cells use 
inﬂ ammatory mechanisms to prevent immune-system 
activation and to protect the tumour from immune attack 
(equilibrium and escape phases).35 Moreover, inﬂ ammatory 
elements (such as chemokines and interleukins) released 
by tumour cells promote inﬁ ltration, progression of 
disease, and metastases (ﬁ gure 2).36
Various mechanisms might exist that exacerbate the 
patho physiological response induced by radiation 
exposure in patients with connective tissue diseases. 
One potential mechanism includes the overexpression of 
proﬁ brotic cytokines, such as transforming growth factor β 
Tumour type Patients with 
connective tissue 
disease (n)
Type of connective 
tissue disease
Increase in 
severe acute 
toxicity
Increase in 
severe late 
toxicity
Treatment Conclusion
Teo et al, 19891 Head and neck 10 Dermatomyositis Yes Yes External-beam radiotherapy Eﬀ ect
Fleck et al, 19892 Breast 9 Mixed Yes Yes External-beam radiotherapy Eﬀ ect
Varga et al, 19913 Mixed 4 Progressive 
systemic sclerosis
No Yes External-beam radiotherapy Eﬀ ect
Hareyama et al, 
19954
Head and neck 2 Mixed Yes No Concurrent chemotherapy and 
external-beam radiotherapy
Inconclusive*
Bliss et al, 19965 Cervix 5 Mixed Yes No External-beam radiotherapy 
and brachytherapy
Eﬀ ect
Turesson et al, 
19966
Breast 35 NA NA No NA No eﬀ ect
Rakfal and Deutsch, 
19987
Mixed 6 Systemic lupus 
erythematosus, 
discoid lupus 
erythematosus 
No No External-beam radiotherapy No eﬀ ect
Khoo et al, 20048 Anal cancer 2 Systemic lupus 
erythematosus
No No Concurrent chemotherapy 
and external-beam 
radiotherapy
No eﬀ ect
Dragun et al, 20119 Breast 9 Mixed No No Intraoperative radiotherapy 
and brachytherapy
No eﬀ ect
Lowell et al, 201110 Brain metastases 14 Mixed No No Gamma knife No eﬀ ect
NA=not available. *Inconclusive eﬀ ect based on presented data.
Table 1: Patient characteristics and ﬁ ndings from selected case studies of patients with connective tissue diseases and cancer reporting toxicity
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(TGFβ) and interleukin 1. Radiation injury in healthy 
tissues is usually characterised by the appearance of a 
ﬁ brinous exudate within the stroma and by deposition of 
extracellular matrix components, including collagen, 
through myo ﬁ broblasts produced by ﬁ broblast activation 
and diﬀ erentiation.37 In some connective tissue diseases 
(such as systemic sclerosis) in which TGFβ concentrations 
are already increased, late eﬀ ects after radiotherapy might 
be more evident.3 Another potential mechanism involves 
radiation microvascular damage in a context of vasculitis, 
leading to increased late eﬀ ects and reduced tolerance to 
treatment. After radiation, endothelial cell injury and 
tissue hypoxia stimulate the recruitment into the tissue of 
inﬂ ammatory circulating cells, such as macrophages, 
which are a source of proﬁ brotic mediators, including 
TGFβ1.38,39 Additionally, increased concentrations of 
proangiogenesis factors (eg, VEGF) as a result of vascular 
damage and leakage of vessels in response to radiotherapy 
could exacerbate late eﬀ ects such as dermal atrophy, 
telangectasia, necrosis, and ﬁ brosis.40 Finally, radiation-
induced damage to basement membranes causes this 
to become a target tissue, leading to increased 
autoimmunity.12,28
Preclinical studies and case reports
Some studies have used in-vitro sensitivity to radiation 
in lymphocytes from patients with connective tissue 
diseases to assess risk indicators for radiation-related 
Primary 
tumour 
site
Patients with 
connective tissue 
disease (n)
Type of connective tissue 
disease (n)
Study design Increase in 
severe acute 
toxicity
Increase in 
severe late 
toxicity
Median 
radiotherapy dose
Radiotherapy 
technique
Conclusion
Ross et al, 
199311
Mixed 61 Rheumatoid arthritis 
(n=39), systemic lupus 
erythematosus (n=13), 
other (n=9)
Matched pair 
analysis
No No 56 Gy External-beam 
radiotherapy, 
brachytherapy
No eﬀ ect
Morris et al, 
199712
Mixed 209 Rheumatoid arthritis 
(n=131), systemic lupus 
erythematosus (n=25), 
other (n=53)
Retrospective No Yes 45 Gy External-beam 
radiotherapy
Inconclusive*
Chen et al, 
200113
Breast 36 Rheumatoid arthritis 
(n=17), systemic lupus 
erythematosus (n=5), 
scleroderma (n=4), other 
(n=10)
Matched pair 
analysis
Yes Yes 64 Gy External-beam 
radiotherapy, 
brachytherapy
No eﬀ ect (eﬀ ect in 
scleroderma)
Phan et al, 
200314
Mixed 38 Systemic lupus 
erythematosus (n=21), 
scleroderma (n=2), other 
(n=15)
Matched pair 
analysis
No No 55·17 Gy External-beam 
radiotherapy, 
brachytherapy
No eﬀ ect (eﬀ ect in 
scleroderma)
Liu et al, 
200415
Prostate 15 NA Prospective No Yes 66 Gy External-beam 
radiotherapy
Eﬀ ect
Benk et al, 
200516
Mixed 38 Systemic lupus 
erythematosus (n=38; 
4 radiotherapy treated)
Retrospective No No NA NA No eﬀ ect
Gold et al, 
200717
Mixed 20 Scleroderma (n=20) Retrospective No No 36 Gy External-beam 
radiotherapy, 
brachytherapy
No eﬀ ect
Lin et al, 
200818
Mixed 73 Rheumatoid arthritis 
(n=33), systemic lupus 
erythematosus (n=13), 
scleroderma (n=9), other 
(n=18)
Retrospective No Yes NA External-beam 
radiotherapy
No eﬀ ect (eﬀ ect 
unknown in pelvic site 
systemic lupus 
erythematosus or 
scleroderma)
Gold et al, 
200819
Mixed 41 Progressive systemic 
sclerosis (n=20), systemic 
lupus erythematosus 
(n=21)
Retrospective NA No NA External-beam 
radiotherapy, 
brachytherapy
Inconclusive*
Pinn et al, 
200820
Mixed 21 Systemic lupus 
erythematosus (n=21)
Retrospective Yes No 49·75 Gy External-beam 
radiotherapy, 
brachytherapy, 
intensity-modulated 
radiotherapy
No eﬀ ect
Patel et al, 
201221
Mixed 12 Discoid lupus 
erythematosis (n=12)
Retrospective No No 69 Gy External-beam 
radiotherapy, 
brachytherapy
No eﬀ ect
NA=not available. *Inconclusive eﬀ ect based on presented data.
Table 2: Eﬀ ect of connective tissue diseases on toxicity after cancer treatments reported in retrospective and matched pair studies
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side-eﬀ ects.41–43 Carrillo-Alascio and colleagues41 used 
pulsed-ﬁ eld gel electrophoresis to quantify the initial 
radiation-induced DNA double-strand breaks in 
peripheral lymphocytes from 52 patients with systemic 
lupus erythematosus. Systemic lupus erythematosus did 
not confer a higher intrinsic risk of radiosensitivity 
when compared with 48 healthy participants without 
connective tissue diseases.41 In another study,43 the same 
investigators carried out an in-vitro evaluation of the 
repair of mainly single-stranded DNA breaks after 
peripheral blood radiation of 48 children with systemic 
lupus erythematosus, systemic sclerosis, juvenile 
rheumatoid arthritis, and dermat omyositis. Greater DNA 
damage and a delay in DNA repair were noted in the 
children with connective tissue diseases group than in 
healthy children.43 Another in-vitro study that used 
tritiated  thymidine incorporation assays showed that 
patients with active systemic lupus erythematosus had 
increased radiotherapy-related lymphocytic sensitivity 
when compared with healthy patients when irradiated 
with ⁶⁰Co-γ photons between 0 Gy and 10 Gy, resulting 
in a potentially higher probability of radiation toxicity.42
Similarly, immune system changes, which can aﬀ ect 
radiosensitivity, are being investigated. Among others, 
Budach and colleagues44 investigated the possibly 
abnormal reaction to high radiation doses in two groups 
of germline mutation-carrying mice, one with severe 
combined immunodeﬁ ciency (SCID; even though it is 
not classiﬁ ed as a connective tissue disease) and one that 
had normal radiation sensitivity (C3H). The lethal dose 
for 50% of the irradiated animals after single-dose 
whole-body irradiation was lower for SCID mice than for 
C3H mice, as was the radiation dose that was needed to 
achieve 50% local control and tumour growth delay, 
Figure 1: Main immune cells, interleukins, and cytokines involved in immune surveillance
TGF=transforming growth factor. IFN=interferon. IL=interleukin. TNF=tumour necrosis factor.
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Figure 2: Tumour-cell mechanisms against the immune system
TGF=transforming growth factor. CXC=CXC chemokine. IFN=interferon. IL=interleukin. TNF=tumour necrosis factor. 
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thus conﬁ rming that abnormal radiation sensitivity 
was observed in SCID mice.44 A possible mechanism 
correlated with increased sensitivity of SCID tumour cell 
lines is the inability of the tumour cells to overcome their 
genetic deﬁ ciency in DNA double-strand break repair in 
SCID ﬁ broblasts.45
More than 300 cases involving patients with connective 
tissue diseases have been published reporting toxicity 
after radiotherapy and several early and late radiotherapy-
related complications, including some deaths, have 
also been reported.2,5,7,10,46 The ﬁ rst two severe events 
in patients with connective tissue diseases given 
radiotherapy were noted in the late 1960s.47,48 In one case, 
a patient with systemic lupus erythematosus who had 
lymphoma died of heart failure 1 year after radiotherapy 
to the mediastinal and retroclavicular nodes (20 Rad 
[20 Gy] and 39 Rad [39 Gy], respectively, with ⁶⁰Co),47 
whereas the second patient, who had facial lupus, 
developed radiotherapy-correlated osteomyelitis of the 
maxilla.48 However, no data about radiotherapy dose or 
modality were provided. Teo and colleagues1 assessed the 
radiation toxicity proﬁ les of ten patients with a diagnosis 
of early-stage nasopharyngeal carcinoma and dermato-
myositis (table 1). At a median follow-up of 51·8 months, 
all patients had subcutaneous ﬁ brosis and xerostomia, 
two patients had radiation skin necrosis, and one patient 
had a VI and XII cranial nerve deﬁ cit.1 However, no 
information was provided about radiotherapy dose 
and techniques.
Fleck and colleagues2 published a study of nine patients 
with breast cancer (four women with a pre-existing 
connective tissue disease and ﬁ ve who developed a 
connective tissue disease after radiotherapy). Eight received 
radiotherapy using ⁶⁰Co with a prescription dose of 
40–50 Gy and an electron boost on the tumour bed of 
5–15 Gy. Three patients with a pre-existing connective 
tissue disease reported a severe toxicity proﬁ le: the ﬁ rst 
case involved  moist desquamation and brachial 
plexopathy; the second case showed soft-tissue necrosis 
needing chest-wall resection, rib fractures, and pulmonary 
ﬁ brosis; and the third patient had soft-tissue necrosis, 
bronchopleural–cutaneous ﬁ stula, and osteonecrosis of 
the clavicle, sternum, and rib. None of the patients with 
a new diagnosis of connective tissue diseases after 
radiotherapy had severe complications.2
According to McCormick,49 to reduce the side-eﬀ ects in 
patients with connective tissue disease and breast cancer, 
a more aggressive local surgery and systemic therapy, in 
particular for younger women (<40 years), was better 
than breast-conserving surgery followed by radiation. 
More recently, accelerated partial breast irradiation by 
either brachytherapy or intraoperative radiotherapy has 
been considered an alternative experimental option for 
the treatment of early-stage breast cancer in women with 
a history of connective tissue diseases. Dragun and 
colleagues9 published a report of nine patients with 
connective tissue diseases with breast cancer given 
accelerated partial breast irradiation via high-dose 
brachytherapy; toxicity and cosmetic proﬁ les were 
reported as satisfactory. Indeed, the authors concluded 
that it might not be necessary to exclude patients with 
connective tissue diseases from clinical trials of 
accelerated partial breast irradiation. As conﬁ rmation, 
Turesson and colleagues6 reported that autoimmune 
disease did not increase the risk of skin teleangectasia in 
35 patients who received radiotherapy for breast cancer. 
Finally, Lowell and colleagues10 published data on the 
use of a very high dose of radiation delivered with 
gamma knife for brain metastases in 14 patients with 
connective tissue diseases, and reported no grade 3 or 4 
toxicity (table 1).
In conclusion, in-vitro studies and clinical case reports 
describe a narrow and heterogeneous picture for patients 
with connective tissue diseases who receive radiotherapy. 
Despite these data limitations, more recently published 
data show that patients with connective tissue diseases 
seem to be less aﬀ ected by toxicity than are healthy 
individuals and case reports (table 1).
Retrospective and controlled studies
To our knowledge, no randomised controlled study has 
assessed whether patients with connective tissue diseases 
are more likely to develop acute or late radiotherapy-
related toxicity. However, we retrieved 11 case series.11–21 
In a retrospective analysis, Morris and Powell12 reported a 
large series of 209 patients with connective tissue diseases 
given radiotherapy with a median radiation dose of 45 Gy 
(range 13–82) between 1960 and 1995. After a median 
follow-up of 6 years, clinically signiﬁ cant acute side-eﬀ ects 
(Radiation Therapy Oncology Group/Eastern Cooperative 
Oncology Group RTOG/ECOG Early Morbidity Scoring 
Scale of more than three) were similar in patients with 
and without rheumatoid arthritis (both 12%). At 5 years, 
the risk of late morbidity for patients with rheumatoid 
arthritis was 6%, similar to the rate for the healthy 
population generally, whereas for patients without 
rheumatoid arthritis it was 21% (p=0·0002). The most 
highly represented connective tissue disease after 
rheumatoid arthritis was systemic lupus erythematosus, 
with 25 patients (12%). No correlation between 
dose, fraction size, irradiated volume, and late eﬀ ects 
were reported.12
Similar results were reported in a matched-control 
study of 61 patients with connective tissue diseases.11 
The number of acute reactions after radiotherapy in the 
connective tissue diseases group was only slightly higher 
than in the matched-control group, with grade 3 or 
greater acute toxicity noted in seven patients in the 
connective tissue diseases group and four in the 
matched-control group. Patients with systemic lupus 
erythematosus had an increase in the number of acute 
reactions due to radiation (36% of patients with systemic 
lupus erythematosus vs 18% in the control group, 
p=0·5), whereas patients with rheumatoid arthritis had 
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an increase in late complications (24% vs 5%; p=0·125). 
Nevertheless, the study showed no signiﬁ cant diﬀ erences 
in acute and late toxicity complications between groups.11
Chen and colleagues13 reported no signiﬁ cant diﬀ erences 
in acute complications after breast cancer radiotherapy 
between a group of 36 women with connective tissue 
diseases and a matched-control group (14% vs 8%, 
respectively; p=0·40), but did note a signiﬁ cant diﬀ erence 
in late toxicity in those patients with connective tissue 
diseases (17% vs 3%; p=0·0095). However, when the 
investigators stratiﬁ ed patients by speciﬁ c autoimmune 
disease, they found a signiﬁ cant diﬀ erence only in four 
patients with scleroderma.13 Phan and colleagues14 
assessed 76 patients who received radiation for cancer 
(38 patients with connective tissue diseases and 38 in the 
control group) and did not show any signiﬁ cant diﬀ erences 
in terms of acute or late complications between groups. 
However, increased risk of radiation complications was 
reported in patients with scleroderma (n=4).
In another study, Lin and colleagues18 reported toxic 
eﬀ ects in 73 patients with connective tissue diseases 
given radiotherapy. No diﬀ erences were noted in acute 
toxicity between patients with connective tissue diseases 
and those in the control group. However, patients with a 
diagnosis of connective tissue diseases had a signiﬁ cantly 
higher incidence of late toxicity compared with the 
control group (29% vs 14%, respectively; p=0·001), with a 
non-signiﬁ cant increase in severe late toxicity (9% vs 4%; 
p=0·079). Patients with diagnosed connective tissue 
diseases who received radiation to the pelvis had a 
higher probability of severe toxicity reactions (grade 3 or 
higher); furthermore, the incidence of severe late toxicity 
was higher in patients with a diagnosis of systemic 
lupus erythematosus and scleroderma than in the 
control group.18
Gold and colleagues19 retrospectively analysed the toxicity 
proﬁ le of 41 patients with connective tissue diseases given 
radiation for cancer (20 patients with systemic sclerosis 
and 21 patients with systemic lupus erythematosus). 
Patients were divided into high-severity and low-severity 
connective tissue diseases on the basis of the number of 
involved organs. Univariate analysis showed a signiﬁ cant 
increase in the risk of any grade toxicity for patients with 
high-severity connective tissue diseases compared with 
those with low-severity connective tissue diseases 
(p=0·006), although no diﬀ erences in grade 3 or higher 
toxicity were found between the two groups (p=0·56). 
Despite the small number of enrolled patients, the severity 
of connective tissue diseases could be considered as an 
important factor in the prediction of treatment tolerability. 
Nonetheless, the severity of connective tissue diseases was 
not a clear contraindication to radiotherapy.19
Varga and colleagues3 reported on the toxicity proﬁ le 
of four patients with systemic sclerosis who were 
given radiotherapy.3 All patients had cutaneous and 
subcutaneous late toxicity, visceral ﬁ brotic reactions at 
the radiation site, and severe skin toxicity and ﬁ brosis 
extending beyond the radiation ﬁ eld involving internal 
organs. Three of the four patients subsequently died, 
two from bowel obstruction and one from pneumonia.3
Liu and colleagues15 planned a prospective study to 
investigate the eﬀ ect of neoadjuvant androgen-deprivation 
therapy and radiotherapy in men with prostate cancer. 
A subanalysis showed that 15 of the men had a connective 
tissue disease and that these patients had a greater 
frequency of late genitourinary grade 2 toxicities 
compared with healthy men (relative risk 3·98; p=0·007).15
As previously stated, several studies have reported 
radiotherapy-related toxicity proﬁ les in patients with a 
range of connective tissue diseases (tables 1, 2). 
Nevertheless, only a few of the studies7,8,17,20 focused on 
patients with scleroderma and systemic lupus 
erythematosus, with contentious conclusions about 
radiotherapy toxicity.
Gold and colleagues17 assessed the toxicity proﬁ les of 
20 patients with scleroderma and cancer who had been 
treated with radiotherapy or brachytherapy or both, with 
or without concurrent chemotherapy. Univariate 
analysis showed a signiﬁ cant association between acute 
toxicity, radiotherapy dose, and increased scleroderma 
involvement of organs. For late side-eﬀ ects, negative 
antinuclear antibody serology was correlated with a 
higher probability of toxicity. None of the analysed 
pretreatment and treatment variables were correlated 
with severe acute and late toxicity.17 There have been no 
further reports to conﬁ rm severe acute and late 
complication proﬁ les in this speciﬁ c setting.7,8,10
Rakfal and Deutsch7 described data for six patients 
who had a diagnosis of systemic lupus erythematosus 
and diﬀ erent malignancies with various radiotherapy 
doses, reporting no unexpected severe acute or late 
side-eﬀ ects. Khoo and colleagues8 reported no relevant 
acute or late complications in two patients with anal 
cancer with systemic lupus erythematosus taking 
concomitant immunosuppressive therapy who were 
treated with combined chemoradiotherapy (⁶⁰Co and 
external-beam radiotherapy).
One of the most important reports was published by 
Pinn and colleagues,20 which included 21 patients with 
systemic lupus erythematosus who received a total of 
35 consecutive courses of radiotherapy. Of the 17 patients 
who were evaluable for late toxicity, four patients (24%) 
had a grade 3 or higher toxicity. The presence of renal 
involvement according to the American Rheumatism 
Association criteria was correlated with an increased risk 
of any grade of late toxicity (p<0·006). Univariate 
analysis established a correlation between acute toxicity 
and total dose (>49·8 Gy), treatment sites, and curative 
intent for treatment. Brachytherapy was used in one 
treatment course, 2D radiotherapy in 30 courses, 
3D conformal radiotherapy in three, and intensity-
modulated radiotherapy in one. Moreover, absence of 
photosensitivity (p<0·02), absence of arthritis (p<0·03), 
and presence of a malar rash (p<0·04) were correlated 
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with an increased risk of grade 3 or greater acute toxicity. 
No speciﬁ c association between technique and late 
toxicity was noted. Radiation dose prescription, radiation 
techniques, and anatomical site (ie, abdomen, pelvis, 
breast, brain, neck, and chest) were associated with a 
high risk of any late toxicity.
In conclusion, the small number of described cases 
and the heterogeneity of the connective tissue disease 
seem to strongly aﬀ ect the statistical power of these 
studies, thus limiting the possibility to show any robust 
association between radiation toxicity and connective 
tissue diseases, and conﬁ rming that radiotherapy is 
frequently withheld unjustly to treat patients with 
connective tissue diseases.16,19,21
Clinical solutions and future perspectives
Various treatment strategies have been considered for 
patients with connective tissue diseases to reduce the 
risk of toxicity during or after radiotherapy such as 
avoiding concomitant treatment or reducing dose 
prescription. Although the use of chemoradiotherapy is 
considered the gold standard in many cases, 
multimodality treatment in patients with connective 
tissue diseases could be correlated with a more severe 
toxicity proﬁ le than single-modality treatment, thereby 
aﬀ ecting its feasibility.4,12,19,50 In radiotherapy, the radiation 
dose could be reduced to lower the toxicity proﬁ le, but 
this could impair eﬀ ectiveness.12,28,44,51 However, Delanian 
and colleagues52 reported that reducing radiation dose 
(from 65 Gy to 40 Gy) in patients with connective tissue 
diseases (one with lung cancer and two with anal–rectal 
cancer) resulted in complete remission, although 
side-eﬀ ects were observed at the radiation site. Some 
investigators have postulated that hyperactivation of the 
immune system by tumour cells makes patients with 
connective tissue diseases more sensitive to radiation 
than others.53,54 Another strategy is changing dose 
fractionation schedules or reducing treatment volume, 
which might decrease toxicity complications.2,12,28,40,51,52,54 
Nevertheless, a crucial question still remains—is it really 
necessary to modify radiotherapy features to decrease 
toxicity in patients with connective tissue diseases?
The most common radiotherapy approach is to use 
external beams to deliver ionising radiation. In the past 
few decades, most departments have replaced their 
⁶⁰Co machines with the more precise linear accelerator. 
Despite modern radiotherapy now being available, most 
reports of patients with connective tissue diseases involve 
obsolete and unsatisfactory technologies including 2D 
radiotherapy. Intensity-modulated radiotherapy and 
stereotactic ablative radiotherapy have allowed radiation 
oncologists to prescribe higher dose prescriptions to 
targets when useful or required. Intensity-modulated 
radiotherapy is considered an advancement of 
3D-conformal radiotherapy that targets the radiation dose 
into the tumour, thus minimising the exposure of healthy 
tissue in several anatomical regions. Intensity-modulated 
radiotherapy is considered the most appropriate 
technique in head and neck cancers and in most pelvic 
tumours, including prostate cancer. In this disease, 
intensity-modulated radiotherapy decreased long-term 
toxicity with no negative eﬀ ect on overall survival when 
compared with 3D-conformal radiotherapy.54–66
Stereotactic ablative radiotherapy is a novel radiotherapy 
method that delivers a very high dose of radiation (in a 
single or a few fractions) with high precision to the 
tumour, thus maximising the sparing of surrounding 
normal tissue. Several retrospective and prospective 
stereotactic ablative radiotherapy studies have shown 
promising results in terms of local tumour control and 
survival in some settings, including in early non-small-cell 
lung cancer.67 Moreover, image-guided radiotherapy based 
on daily patient set-up position veriﬁ cation allowed better 
deﬁ nition of the tumour target to reduce and ultimately 
eliminate uncertainties. To our knowledge, no randomised 
controlled trials using image-guided radiotherapy have 
assessed toxicity and eﬃ  cacy in patients with connective 
tissue disease. Hence, the promising, modern techniques 
could improve radiotherapy tolerability, especially in 
challenging clinical situations, as well as in patients with 
connective tissue diseases and cancer.68,69
Conclusion
The data that are currently available from case series 
and a few retrospective studies are still not enough to 
support a speciﬁ c contraindication for radiotherapy in 
patients with connective tissue diseases. Nevertheless, 
a cautious approach for patients with active connective 
Search strategy and selection criteria
We searched Medline, Google Scholar, PubMed, and the ProQuest Dissertation, and 
Theses databases for reports published in English from June, 1946, to Jan 1, 2015. 
Our detailed search algorithm is shown in the appendix. We identiﬁ ed additional 
references with a manual review of the reference lists of included articles. 
Two independent reviewers (NGL and SS) identiﬁ ed potential studies and exported them 
to an electronic reference management software program (RefWorks version 2.0). 
NGL and SS determined eligibility by reviewing ﬁ rst the title and abstract and then the full 
paper. Disagreements were resolved by consensus; if consensus was not achieved, then a 
third author (FA) provided an assessment of eligibility. Because the data for eligibility 
were dichotomous (yes vs no), we established inter-rater agreement at both the title and 
abstract review and the full article review stages by calculating Cohen’s κ coeﬃ  cient. 
A study was included when it reported on cancer-related radiotherapy and included 
patients with connective tissue diseases. A study was excluded when no detailed 
information (eg, outcome of radiotherapy, clinical manifestations related to the 
underlying connective tissue diseases, solid evidence of diagnosis of connective tissue 
diseases) was reported. Review articles were excluded from the analysis. For data 
extraction, all the papers were scrutinised for the following information: study design 
(retrospective, prospective, case-control, cross-sectional and case series, or case report); 
number of patients, sex, and age (mean, range); type of radiotherapy; type of underlying 
connective tissue disease; type of underlying cancer; deﬁ nition of radiotherapy acute and 
late toxicity proﬁ le; outcome in terms of toxicity proﬁ le; and timing of connective tissue 
diseases onset or exacerbation.
For more on Cohen’s κ coefficient 
see http://facultyvassaredu/lowry/
kappa.html
See Online for appendix
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tissue diseases seems to be reasonable. Moreover, the 
recent implementation of new radiotherapy approaches 
could be promising to improve the feasibility and 
tolerability of radiotherapy in some patients with 
cancer, including those with connective tissue diseases. 
Further well designed prospective studies, which also 
assess the most appropriate total dose and fractionation 
schedules, will probably help to overcome the 
unresolved concerns about radiotherapy indication for 
patients with connective tissue diseases.
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